Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ABVC vs CNVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CNVS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

CNVS Overall Winner 6-Pillar Tally: ABVC 1 – 5 CNVS Matrix Metrics: ABVC 4 – 6 CNVS

As of Nov 20, 2026, Cineverse Corp. (CNVS) is the stronger overall head-to-head candidate over ABVC BioPharma, Inc. (ABVC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ABVC carries a Unified Composite Score of 47.4/100 (HOLD) at $0.87 (N/M Forward P/E, 0.0% operating margin), whereas CNVS carries 35.9/100 (SELL) at $1.73 (38.8x Forward P/E, -12.0% operating margin).

  • Composite vs. Pillar Nuance: While ABVC currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. CNVS 35.9/100 SELL), CNVS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-12.0% vs. 0.0% operating margin) and revenue trajectory (+110.0% vs. +104.5% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABVC vs CNVS
ABVC NASDAQ
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.87
-1.56% 1D
Market Cap $23.9M
TTM Revenue $797,916
Forward P/E N/M
Beta / 30D Vol 1.24β · 44% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 43.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.2 · SMA20: $0.98 · SMA50: $1.01
CNVS NASDAQ Head-to-Head Winner
Cineverse Corp. Class A Common Stock
Services-Video Tape Rental
$1.73
-5.46% 1D
Market Cap $49.1M
TTM Revenue $99M
Forward P/E 38.8x
Beta / 30D Vol 1.19β · 110% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 15.0 Fund 36.0 Flow 54.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $1.70 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (ABVC 1 – 5 CNVS)

Columns: Metric · ABVC · CNVS
1. Valuation Multiples CNVS
Forward P/E N/M 38.8x
Trailing P/E N/M 38.8x
PEG Ratio N/M 0.46x
EV / Revenue 29.9x 0.7x
2. Growth & Scale CNVS
Revenue Growth (YoY) +104.5% +110.0%
Earnings Growth (YoY) +0.0% +21.1%
TTM Revenue (USD) $797,916 $99M
Market Cap $23.9M $49.1M
3. Profitability & Quality ABVC
Gross Margin 100.0% 42.7%
Operating Margin 0.0% -12.0%
Net Profit Margin 0.0% -2.1%
Return on Equity (ROE) -52.7% -4.6%
4. Balance Sheet & Cash Flow CNVS
Cash Generation (TTM) -$5.8M EBITDA -$18M
Cash Flow Margin N/A -17.9%
Net Cash / Leverage $0.50 Book/Sh · -52.7% ROE $22M Net Debt (0.65x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CNVS
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 131.8% (28th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CNVS
OpEx & R&D Intensity N/A 54.7% of Rev ($54M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Entertainment Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABVC (4) vs CNVS (6)
Institutional Metric ABVC CNVS Criterion Row Edge
Market Capitalization
Scale
$23.9M $49.1M Larger Scale CNVS
Trailing P/E Ratio
Valuation
N/M 38.8x Lower Multiple CNVS
Forward P/E Ratio
Valuation
N/M 38.8x Lower Multiple CNVS
Revenue Growth (YoY)
Growth
+104.5% +110.0% Higher Growth CNVS
Operating Margin (TTM)
Profitability
0.0% -12.0% Higher Margin ABVC
Net Profit Margin
Profitability
0.0% -2.1% Higher Margin ABVC
Return on Equity (ROE)
Capital Efficiency
-52.7% -4.6% Higher ROE CNVS
52-Week Range Position
Momentum
7% ($1–$3) 16% ($1–$3) Stronger Trend CNVS
Beta / 30D Volatility
Risk Regime
1.24β · 44% Vol 1.19β · 110% Vol Lower Realized Risk ABVC
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite ABVC
Trailing 12M Revenue (USD)
Operating Scale
$797,916 $99M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 42.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.9x EV/Rev 0.46x PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$5.8M EBITDA ($0.50 Book/Sh · -52.7% ROE) -$18M ($22M Net Debt (0.65x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CNVS +29.62 pp
ABVC: -17.28% · CNVS: +12.34%
3M Horizon ABVC +35.02 pp
ABVC: +3.13% · CNVS: -31.89%
6M Horizon ABVC +5.38 pp
ABVC: -24.01% · CNVS: -29.39%
1Y Horizon CNVS +35.73 pp
ABVC: -68.15% · CNVS: -32.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABVC vs CNVS. Trailing 12-month operating profitability (ABVC 0.0% vs CNVS -12.0%) and valuation multiples (ABVC N/M vs CNVS 38.8x Forward P/E) are benchmarked directly in Pillar 4 below.

ABVC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$797,916
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-52.7% · N/M
CNVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$99M
Gross Margin42.7%
Op. Margin-12.0%
ROE / Fwd P/E-4.6% · 38.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABVC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CNVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 131.8%
IV Percentile 28th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact CNVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABVC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $23.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CNVS Moat Profile Cyclical / Execution-Driven Positioning
Entertainment Operator
Competes within the Entertainment value chain with $49.1M market capitalization and -12.0% operating margin.
OpEx & R&D Reinvestment 54.7% of Rev ($54M)
90D Engineering Disclosures 0 Published

Investor FAQ ABVC vs CNVS Key Questions & Quantitative Answers

As of Nov 20, 2026, Cineverse Corp. (CNVS) is the stronger overall head-to-head candidate over ABVC BioPharma, Inc. (ABVC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ABVC carries a Unified Composite Score of 47.4/100 (HOLD) at $0.87 (N/M Forward P/E, 0.0% operating margin), whereas CNVS carries 35.9/100 (SELL) at $1.73 (38.8x Forward P/E, -12.0% operating margin). Composite vs. Pillar Nuance: While ABVC currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. CNVS 35.9/100 SELL), CNVS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-12.0% vs. 0.0% operating margin) and revenue trajectory (+110.0% vs. +104.5% YoY).

CNVS leads the Growth & Scale pillar: ABVC posts +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin), compared with CNVS at +110.0% YoY revenue growth and +21.1% YoY earnings growth on $99M TTM revenue (42.7% gross margin, -12.0% operating margin). On trailing 12-month operating scale, ABVC generates $797,916 in USD-normalized revenue versus $99M for CNVS. In operating R&D and SG&A reinvestment, ABVC deploys N/A (0 90-day corporate R&D disclosures) versus 54.7% of Rev ($54M) (0 disclosures) for CNVS.

CNVS screens cheaper on headline valuation multiples. ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.9x EV/Revenue (unreported EBITDA margin), whereas CNVS trades at 38.8x Forward P/E, 38.8x Trailing P/E, 0.46x PEG, and 0.7x EV/Revenue (-17.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABVC (-52.7% ROE) versus CNVS (-4.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.24β · 44% Vol realized risk). By comparison, CNVS carries 131.8% implied volatility (28th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 110% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.